18F-FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy

Not Recruiting

Trial ID: NCT01806675,7,8,9,18,20,22,30,45,62,80,45550


The purpose of the study is to conduct research of a new PET radiopharmaceutical in cancer patients. The uptake of the novel radiopharmaceutical 18F-FPPRGD2 will be assessed in study participants with glioblastoma multiforme (GBM), gynecological cancers, and renal cell carcinoma (RCC) who are receiving antiangiogenesis treatment.

Official Title

Phase 1-2 18F-FPPRGD2 PET/CT or PET/MRI Imaging of αvβ3 Integrins Expression as a Biomarker of Angiogenesis

Stanford Investigator(s)

Heather Wakelee
Heather Wakelee

Winston Chen and Phyllis Huang Professor

Melinda L. Telli, M.D.
Melinda L. Telli, M.D.

Professor of Medicine (Oncology)

Lawrence Recht, MD
Lawrence Recht, MD

Professor of Neurology (Adult Neurology) and, by courtesy, of Neurosurgery

Andrei Iagaru
Andrei Iagaru

Professor of Radiology (Nuclear Medicine)


Inclusion Criteria:

   - Provides written informed consent

   - Diagnosed with advanced NSCLC, breast cancer, GBM or other cancers (such as head and
   neck, colorectal, pancreatic, renal cancers); patients will undergo anti-angiogenesis
   treatment or treatment with other drugs that may alter angiogenesis

   - Able to remain still for duration of each imaging procedure (about one hour)

Exclusion Criteria:

   - Pregnant or nursing

   - Contraindication to MRI

   - History of renal insufficiency (only for MRI contrast administration)


drug: 18F-fludeoxyglucose (18F-FDG)

drug: 18F-FPPRGD2

Not Recruiting

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305

New Trial Alerts

Receive email alerts when trials open to patients.